Results 51 to 60 of about 28,609 (228)
Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database [PDF]
, 2014 # Background Pulmonary arterial hypertension (PAH) is a disease characterized by dyspnea, fatigue, chest pain and syncope. As there is no known cure for PAH, the goal of treatment is to control symptoms and slow disease progression.
Simon Teal +4 more
core
, 2014 The objective of the present work is to describe the experience with intravenous (IV) sildenafil in heart transplant (HT) patients with reactive pulmonary hypertension (PH) who developed right ventricular dysfunction (RVD) in the immediate postoperative ...
Faisa Osseyran +9 more
core +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
Journal of Pediatric and Neonatal Individualized Medicine, 2015 We report the use of oral sildenafil in a 7-month-old preterm newborn with severe bronchopulmonary dysplasia and pulmonary arterial hypertension refractory to captopril and inhaled budesonide, and need of consistent oxygenation.
Galina A. Alyamovskaya +3 more
doaj +1 more source
Effect of sildenafil on IUGR [PDF]
, 2017 Background: IUGR is one of the major culprit of perinatal mortality and morbidity in India, with reported incidence of 21-28%. Objective of present study is to investigate the effect of sildenafil on pregnancies complicated with IUGR and to see its ...
Kujur, Avinashi +7 more
core +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Stem Cell Research & TherapyBackground Osteoporosis, a common bone disorder, is primarily managed pharmacologically. However, existing medications are associated with non-trivial side-effects.
Menglong Hu +9 more
doaj +1 more source
Sildenafil citrate: A therapeutic update
, 2001 Background: Since its approval by the US Food and Drug Administration in March 1998, sildenafil citrate has been used by millions of men for the treatment of erectile dysfunction.
Umland, Elena M., Boyce, Eric G.
core +1 more source
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Objective This study aimed to describe maternal and perinatal outcomes among pregnant women with echocardiographically high probability of pulmonary arterial hypertension (PAH) managed at a quaternary center and to compare outcomes between women with and without cardiac complications (CC).
Laura Belmont‐Rojo +6 more
wiley +1 more source
Effect of sildenafil in cavernous arteries of patients with erectile dysfunction
International Brazilian Journal of Urology, 2003 INTRODUCTION: Sildenafil citrate is a type 5 phosphodiesterase inhibitor, which has demonstrated excellent results in the treatment of erectile dysfunction.
Joaquim A Claro +5 more
doaj +1 more source